FDA warns Curaleaf about inflated claims in CBD product marketing
4 years ago
16
A major medical marijuana company is under fire from the FDA. The agency sent Curaleaf a letter of warning over concerns that the cannabis company is marketing some of its products containing CBD as being effective treatments for cancer, Alzheimer's disease, opioid withdrawal and pain.
Loading comments...
-
1:26
WFTX
4 years agoFDA warns Curaleaf about inflated claims in CBD product marketing
32 -
1:48
WFTX
4 years agoFDA warns Curaleaf about inflated claims in CBD product marketing
19 -
0:30
BPR
4 years agoFDA warns Purell about making claims about diseases
4.47K -
0:33
New York Post
2 years agoDEA warns of 'alarming increase' in fake prescription pills containing fentanyl
7785 -
1:31
Just the News
1 year agoDEA releases warning after law enforcement seizes candy-like fentanyl
5805 -
0:46
NextNewsNetwork
2 months agoCall for FDA Action on Decaf Coffee Carcinogen
8113 -
1:00
SusieQ4u
1 year agoTHE FDA IS CLAIMING NOW THAT ALL HOMEOPATHIC PRODUCTS ILLEGAL
53 -
40:24
Niko House
4 months agoBREAKING: CDC LOOKS THE OTHER WAY AFTER ILLEGAL BIOLAB CONTAINING COVID DISCOVERED IN CALIFORNIA
136 -
47:46
Slavica Vukmanovic
1 year agoExposing the FDA, Pharmaceuticals and the MD
20 -
2:35
TheWarAgainstYou
10 months agoFDA Knowingly Pushes Tainted Drugs. Shortages Mean Ignored Risks by FDA
1.8K2